



Common Drug Review *

Submission Status

Product:	DuoTrav		
Generic Name:	travoprost/timolol maleate		
Manufacturer:	Alcon Canada Inc.		
Submission Type:	New		
Date Submission Received:	2006-Mar-24	Date NOC Issued:	2006-Mar-17
Targeted CEDAC Meeting:	2006-Jul-26	Priority Review Granted:	Not requested

Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments	
1	Submission Deemed Complete	5	2006-Mar-31	2006-Apr-03	
2	CDR Reviewers' Reports Completed <ul style="list-style-type: none"> • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer 	45	2006-Jun-07	2006-Jun-07	Additional information requested May 19, 2006. Additional information received May 31, 2006.
3	Comments from Manufacturer on Reviewers' Reports Received by CDR	7	2006-Jun-16	2006-Jun-16	
4	Reviewers' Reply to Manufacturer's Comments Completed	7	2006-Jun-27	2006-Jun-26	
5	CEDAC Brief Completed and Sent to CEDAC Members	5	2006-Jul-12	2006-Jul-12	
6	CEDAC Meeting		2006-Jul-26	2006-Jul-26	
7	CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer	5	2006-Aug-2	2006-Aug-02	
8	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation	10	2006-Aug-17	2006-Aug-17	
9 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5	2006-Aug-24	2006-Aug-24	Notice of Final Recommendation issued.
OR					
9 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
OR					
9 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
10	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5			

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.

*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.